239 related articles for article (PubMed ID: 27311467)
1. In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs.
Pizzo F; Benfenati E
Methods Mol Biol; 2016; 1425():163-76. PubMed ID: 27311467
[TBL] [Abstract][Full Text] [Related]
2. In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs.
Pizzo F; Gadaleta D; Benfenati E
Methods Mol Biol; 2022; 2425():241-258. PubMed ID: 35188636
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo Models for Sub-Chronic Repeated-Dose Toxicity: Systemic and Organ-Specific Toxicity.
Selvestrel G; Lavado GJ; Toropova AP; Toropov AA; Gadaleta D; Marzo M; Baderna D; Benfenati E
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743059
[TBL] [Abstract][Full Text] [Related]
4. Study parameters influencing NOAEL and LOAEL in toxicity feeding studies for pesticides: exposure duration versus dose decrement, dose spacing, group size and chemical class.
Zarn JA; Engeli BE; Schlatter JR
Regul Toxicol Pharmacol; 2011 Nov; 61(2):243-50. PubMed ID: 21875639
[TBL] [Abstract][Full Text] [Related]
5. Chemical warfare agents: estimating oral reference doses.
Opresko DM; Young RA; Faust RA; Talmage SS; Watson AP; Ross RH; Davidson KA; King J
Rev Environ Contam Toxicol; 1998; 156():1-183. PubMed ID: 9597943
[TBL] [Abstract][Full Text] [Related]
6. Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug development.
Glatard A; Berges A; Sahota T; Ambery C; Osborne J; Smith R; Hénin E; Chen C
Toxicol Appl Pharmacol; 2015 Oct; 288(2):240-8. PubMed ID: 26232187
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the LOAEL-to-NOAEL uncertainty factor for mild adverse effects from acute inhalation exposures.
Alexeeff GV; Broadwin R; Liaw J; Dawson SV
Regul Toxicol Pharmacol; 2002 Aug; 36(1):96-105. PubMed ID: 12383722
[TBL] [Abstract][Full Text] [Related]
8. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of subchronic toxicity data using the benchmark dose approach.
Gephart LA; Salminen WF; Nicolich MJ; Pelekis M
Regul Toxicol Pharmacol; 2001 Feb; 33(1):37-59. PubMed ID: 11259178
[TBL] [Abstract][Full Text] [Related]
10. Embryonic delivered dose of isotretinoin (13-cis-retinoic acid) and its metabolites in hamsters.
Eckhoff C; Willhite CC
Toxicol Appl Pharmacol; 1997 Sep; 146(1):79-87. PubMed ID: 9299599
[TBL] [Abstract][Full Text] [Related]
11. Developmental toxicity evaluation of emodin in rats and mice.
Jahnke GD; Price CJ; Marr MC; Myers CB; George JD
Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):89-101. PubMed ID: 15098202
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the uncertainty factor for subchronic-to-chronic extrapolation: statistical analysis of toxicity data.
Pieters MN; Kramer HJ; Slob W
Regul Toxicol Pharmacol; 1998 Apr; 27(2):108-11. PubMed ID: 9671565
[TBL] [Abstract][Full Text] [Related]
13. A proposal for calculating the no-observed-adverse-effect level (NOAEL) for organic compounds responsible for liver toxicity based on their physicochemical properties.
Jakubowski M; Czerczak S
Int J Occup Med Environ Health; 2014 Aug; 27(4):627-40. PubMed ID: 25055806
[TBL] [Abstract][Full Text] [Related]
14. Chronic oral LOAEL prediction by using a commercially available computational QSAR tool.
Rupp B; Appel KE; Gundert-Remy U
Arch Toxicol; 2010 Sep; 84(9):681-8. PubMed ID: 20224925
[TBL] [Abstract][Full Text] [Related]
15. Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs).
Bercu JP; Morinello EJ; Sehner C; Shipp BK; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S48-56. PubMed ID: 27233925
[TBL] [Abstract][Full Text] [Related]
16. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction.
Venkatapathy R; Moudgal CJ; Bruce RM
J Chem Inf Comput Sci; 2004; 44(5):1623-9. PubMed ID: 15446819
[TBL] [Abstract][Full Text] [Related]
18. Integration of read-across and artificial neural network-based QSAR models for predicting systemic toxicity: A case study for valproic acid.
Hisaki T; Kaneko MAN; Hirota M; Matsuoka M; Kouzuki H
J Toxicol Sci; 2020; 45(2):95-108. PubMed ID: 32062621
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the dose decrement in regulatory rat pesticide toxicity feeding studies.
Zarn JA; Engeli BE; Schlatter JR
Regul Toxicol Pharmacol; 2013 Nov; 67(2):215-20. PubMed ID: 23911766
[TBL] [Abstract][Full Text] [Related]
20. [A study of the relationships between exposure periods and no-effect doses in repeated dose toxicity tests].
Aida Y; Kamata E; Nakadate M
Eisei Shikenjo Hokoku; 1992; (110):48-53. PubMed ID: 1364436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
